Abstract
Despite great expectations and research efforts, anticancer immunotherapy has not yet become a definitive cure. Perhaps, this is because past reductionist approaches were too simplistic for the patient-specific complex system of coevolving tumor cells and host immunity. Recent efforts based on a systems-based approach promise improved clinical outcomes engendered by a dynamic modification of personalized therapeutic regimens.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1169-1171 |
| Number of pages | 3 |
| Journal | OncoImmunology |
| Volume | 1 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2012 |
Keywords
- Clinical trial
- In-treatment
- Mathematical model
- Personalization
- Prostate cancer
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology